Bicycle therapeutics expands neuroscience collaborations to include oxford university’s oxford drug discovery institute

Bicycle therapeutics plc announced that it will collaborate with oxford university’s oxford drug discovery institute (oddi) to use bicycle technology for the development of novel therapeutics for dementia. this expands upon the collaboration between bicycle and the dementia discovery fund, or ddf, a specialized venture capital fund focused on discovering and developing novel therapies for dementia, announced in may. under the terms of the agreement, bicycle will use its novel and proprietary screening platform to identify bicycles that bind to clinically validated dementia targets. oddi, with its expertise in cns disease, will then profile these bicycles in a range of target-specific and disease-focused assays to determine their therapeutic potential. if promising lead compounds are identified, bicycle will have rights to the development of the resulting intellectual property and, with ddf, will have the option to jointly establish a new company to develop those compounds.
BCYC Ratings Summary
BCYC Quant Ranking